Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Report and Forecast 2024-2032

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook

The global epidermal growth factor receptor (EGFR) inhibitors market is projected to grow at a CAGR of 8.6% during the forecast period of 2024-2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The growing incidences of cancer globally, along with the increasing geriatric population and lifestyle changes are some of the major drivers for the industry growth. Epidermal growth factor inhibitors (EGFRI) is the first targeted cancer therapy, which has become an essential treatment for many advance-stage epithelial cancers. In comparison to conventional chemotherapies, these agents have the superior ability to target cancer cells, further offering better safety profile to the patients.

Market Segmentation

Epidermal growth factor receptor (EGFR) inhibitors are medicines that slow down or stop EGFR’s activity, a protein found on the surface of some normal cells, by binding to its certain part. EGFR or epidermal growth factor receptor causes cells to divide upon binding to it by signalling pathways that control cell division and survival, leading to the growth of normal cells. Certain mutations in EGFR are known to be vulnerable and can lead to the growth of cancer cells.

The global epidermal growth factor receptor (EGFR) inhibitors industry can be divided based on segments like indication and region.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on indication, the industry can be segmented into:

• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Others

The EMR report looks into the regional epidermal growth factor receptor (EGFR) markets like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

Market Analysis

The global epidermal growth factor receptor inhibitors industry is being supported by the increase in the number of cancer cases such as lung cancer, colorectal cancer, breast cancer, and others. The growing incidences of cancer throughout the world also calls for more efficient therapy techniques that encourage scientists to create EGFR antibodies. Because of the busy lifestyle, excessive alcohol consumption and smoking habits, the incidence of cancer is quickly growing, particularly in regions like North America and Europe. The increasing morbidity and mortality rates among patients with cancer are leading to enhanced demand for EGFR antibodies, thus driving the market forward. Due to an enormous unmet need for new therapies to treat cancer symptoms, several pharmaceutical companies are focusing on the development of advanced EGFR inhibitors to capitalise on this enormous unmet need, which is expected to aid the industry over the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

The report presents a detailed analysis of the following key players in the global epidermal growth factor receptor (EGFR) inhibitors market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Amgen Inc. (NASDAQ: AMGN)
• AstraZeneca 
• Eli Lilly and Company 
• F. Hoffmann-La Roche Ltd. 
• Novartis AG
• Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report